Antibodies stimulate microglia to degrade Alzheimer’s amyloid plaques
A novel antibody has been shown to stimulate microglia to degrade amyloid plaques in a murine model of Alzheimer’s disease.
List view / Grid view
A novel antibody has been shown to stimulate microglia to degrade amyloid plaques in a murine model of Alzheimer’s disease.
Scientists have showed that a three inhibitors (3i) cocktail could reprogramme fibroblasts to a naïve embryonic stem cell-like state and remove disease-associated epigenetic changes.
A novel therapy, tested ex vivo, has been successful at correcting the dysfunctional body mechanism in Postural Orthostatic Tachycardia Syndrome (POTS).
A new microfluidic technology has been developed by researchers, which utilises magnetic ferrobots to automate chemical analyses and assays.
Scientists suggest competence-blocking, ‘anti-evolution’ drugs could be administered alongside antibiotics to prolong the period before bacterial resistance emerges.
The first drug designed using artificial intelligence (AI) has moved into its Phase I trial. Professor Andrew Hopkins of Exscientia explains how an algorithm was used to achieve this milestone.
The model was tested on a panel of drugs that are both still on the market or have been recalled due to adverse effects and was able to show their toxicity.
Rodent models of stroke and hydrocephalus treated with ZT-1a had reduced brain swelling, according to scientists.
Dr Nicolas Poirier reveals how immunotherapies can be designed to recalibrate the immune system for long-term maintenance of autoimmune remission.
International collaboration has shown that compounds with metals in them show antibacterial activity against MRSA, E. coli and A. baumannii.
A new study has revealed how bacterial immune systems can be harmful for their hosts and why they are not found in all bacteria.
Drug Target Review’s round-up of the latest developments in 2019 novel coronavirus (COVID-19 or SARS-CoV-2) therapeutics and vaccines.
Drug Target Review spoke with CUE Biopharma’s President and CSO to find out how and why they created the ImmunoSTAT platform and the ways it may benefit drug design in the future.
Researchers have shown that, when treated with L-serine, a non-human primate model of ALS had fewer pathologies associated with the disease.
More effective drugs could be developed due to a new technique that has allowed scientists to decipher how millions of individual cells are communicating with each other on miniature tumours grown in a lab.